-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Proteinuria is often a component of diabetic nephropathy
.
In observational studies and clinical trials, regardless of whether people with diabetes, the presence of albuminuria are associated with adverse renal and cardiac vascular risk (CV) outcomes associated with increased, while reducing the incidence of proteinuria and renal adverse CV outcomes Decrease related
Proteinuria is often a component of diabetic nephropathy
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) can reduce the risk of adverse renal outcomes in patients with type 2 diabetes, including reducing the deterioration of estimated glomerular filtration rate (eGFR) and progression to end-stage renal disease (ESKD)
The effect of dapagliflozin on cardiovascular events (DECLARE-TIMI 58) is a trial for 17,160 patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) (59.
4%) or established ASCVD (eASCVD).
) (40.
6%) of CVOT, which proved that one of the two main curative effects of CV death and heart failure hospitalization was significantly reduced by 17%
.
.
It proved that one of the two main curative effects of CV death and heart failure hospitalization was significantly reduced by 17%
DECLARE-TIMI 58 randomly assigned 17160 patients with type 2 diabetes, creatinine clearance rate >60 ml/min, and atherosclerotic cardiovascular disease (CVD; 40.
6%) or CVD risk factors (59.
4%) to reach Gligliflozin Or the placebo group
.
Urine protein-creatinine ratio (UACR) was tested at baseline, 6 months, 12 months, and every year thereafter
Results A total of 16643 (98.
15%) participants were included in the baseline UACR: 9067 (53.
83%) ≤15 mg/g, 2,577 (15.
30%) >15 to <30 mg/g, 4,030 (23.
93%) 30-300 mg/g, and 1,169 (6.
94%) >300 mg/g
.
As a continuous variable, compared with placebo, the use of dapagliflozin improved from baseline to 4.
Compared with placebo, the use of dapagliflozin improved from baseline to 4.
Changes in UACR of each treatment group at baseline UACR, 6 months, 1 year, 2 years, 3 years, and 4 years
Among them, dapagliflozin compared with placebo, UACR continued to confirm ≥1 category improvement is more common (OR=1.
45[95% CI 1.
35-1.
56], P<0.
0001)
.
In the subgroup with UACR≥30 mg/g, the use of dapagliflozin can reduce the heart and kidney outcomes (P<0.
In the subgroup with UACR≥30 mg/g, the use of dapagliflozin can reduce the heart and kidney outcomes (P<0.
In DECLARE-TIMI 58, dapagliflozin showed beneficial effects on various baseline UACR and kidney-specific results, including patients with normal protein excretion
references:
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
Leave a message here